{
  "id": 21270895,
  "title": "StockWatch: Insmed Jumps on Report of Takeover Interest by Sanofi, as Analysts Conclude a Deal Would Make Sense",
  "url": "https://urgent.news/2026/11/22/stockwatch-insmed-jumps-on-report-of-takeover-interest-by-sanofi-as",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-22T18:52:58.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/translational-medicine/stockwatch-insmed-jumps-on-report-of-takeover-interest-by-sanofi-as-analysts-conclude-a-deal-would-make-sense/"
  },
  "original_language": "en",
  "account": "In the past twenty-one months, Insmed (Nasdaq: INSM), a developer of respiratory, immunology and inflammation drugs, has been on Sanofi (Euronext Paris: SAN and Nasdaq: SNY)’s radar as a potential takeover target. Bloomberg News reported that the French pharmaceutical giant was considering a deal that could be the largest merger-and-acquisition (M&A) since Pfizer’s $43 billion purchase of Seagen in 2023. While the deal is still in the early stages, Insmed’s stock surged 21.5% after the report, climbing from $119.80 on Wednesday to $144.46 on Thursday before settling at $141.33 by week’s end.\n\nAnalysts believe Sanofi would be a rational fit for Insmed due to the overlap in their respiratory franchises. Brinsupri, Insmed’s marketed drug for non-cystic fibrosis bronchiectasis (NCFB), accounted for 73% of the company’s $1.256 billion in Q1-Q3 2026 revenue, a 29% increase from the previous quarter. Sanofi recorded $6.5 billion in global sales for Dupixent, a respiratory drug it co-markets with Regeneron, during the first nine months of 2026. Both companies have strong pulmonary commercial footprints, which could create synergies in the market.\n\nHowever, Sanofi faces challenges, including clinical failures and the expiration of patents on its key drugs. Insmed, on the other hand, has shown success in bringing treatments to market, with Brinsupri recently approved by the FDA. Insmed’s CEO, Will Lewis, expressed optimism about the drug's potential, stating that it has already reached \"blockbuster\" status with over $1 billion in revenue. If the deal goes through, Insmed’s investors believe it could be a strategic move for both companies.",
  "summary": "Bloomberg News cited unnamed sources in reporting that Sanofi (Euronext Paris: SAN and Nasdaq: SNY) was weighing whether to acquire Insmed, in a potential blockbuster deal that the news outlet and others speculated could be biopharma's largest merger-and-acquisition (M&A) deal since 2023. The post StockWatch: Insmed Jumps on Report of Takeover Interest by Sanofi, as Analysts Conclude a Deal Would…",
  "key_points": [
    "Sanofi considering $43B takeover of Insmed, largest M&A since 2023",
    "Insmed's Brinsupri drug accounts for 73% of $1.256B revenue",
    "CEO Will Lewis optimistic, calling Brinsupri a \"blockbuster\""
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}